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monthly interval for blood pressure and heart rate and proteinuria
was assessed at six month.
Results: Both the groups were well matched in term of sex, age,
and weight. Both cilnidipine and amlodipine significantly reduced
both systolic and diastolic blood pressure. Pulse rate were higher
in patient treated with amlodipine than the patient treated with
cilnidipine. Cilnidipine decreased proteinuria which was not seen
in patient on amlodipine.
Conclusion: Thus, study showed that cilnidipine which is Land N
type calcium channel inhibitor is better than amlodipine which L
type of calcium channel inhibitor in patient having cardiovascular
disease, diabetes and renal disease and is better alternative to
amlodipine.
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Background: Complete Heart Block (CHB) is a condition in which
the impulse generated in the SA node does not propagate to the
ventricles. Causes include coronary ischemia, idiopathic degen-
eration of AV node and others. Symptomatic patients were
advised Permanent pacemaker insertion. Most have high blood
pressure as per Marey’s law (1961).
Aim: To assess the effect of permanent pacing VVI mode in CHB
patients on central systolic pressure, pulse pressure and arterial
stiffness and to assess the effect of vasodilator therapy in reducing
arterial stiffness in CHB patients on Permanent pacing VVI mode.
Methods: This study is a prospective analytical study done in
Department of Cardiology at single-centre tertiary care hospital
setting from January 2014 to July 2014. 18 consecutive patients
with CHB before and after permanent pacemaker (VVI mode)
insertion were included. Baseline characteristics like Brachial
Systolic Blood Pressure (SBP), Central SBP, Central pulse pressure
(PP), Augmentation pressure (AP), Augmentation Index(AI) and
Heart Rate were measured before and 10 days after pacemaker
insertion. Brachial SBP was measured with Sphygmomanometer
and Central Pressure and stiffness measured using Sphygmocor
device (Excel) which derives central parameters by FDA approved
transfer function. Data were presented as mean ± 1SD and the
characteristics were compared using t test. A p value of less than
0.05 was considered statistically significant. Diabetic patients
were excluded from study.
Results: Out of 18 Patients, mean age was 59yrs (lowest 27yrs and
highest 80yrs), 11 were males and 7 were females.
Conclusion: Insertion of Permanent Pacemaker Insertion VVI
mode shows significance reduction in Central systolic pressure
and arterial stiffness. Based on Central Blood Pressure and Arterial
stiffness assessment some patient needed vasodilators to reduce
arterial stiffness after Permanent pacing.
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Background: ARBs have been included as a first-line therapy in JNC
8. Additionally, the 2014 ASH/ISH guidelines recommend that ARBs
shouldbepreferredoverACE-I if theyareavailable andaffordable as
they do not cause cough and only rarely cause angioedema, and
haveeffects andbenefits similar toACE-I.Currently there isadearth
of data regarding the use of ARBs as monotherapy or combination
therapy for the treatment of hypertension in India.
Methods: A prescription research survey was conducted amongst
physicians in India to obtain insights about the use of ARBs and
their combinations in clinical practice. The study was conducted
through a survey questionnaire consisting questions on use of
ARBs as an antihypertensive, including preferences of molecules
amongst the ARBs and the combinations of ARBs used for the
management of hypertension with/without comorbid conditions.
Results: The survey questionnaire was answered by 409 physi-
cians. ARBs are preferred as the first-line antihypertensive in
Baseline After treatement
Amlodepine(n-24) Cilnidipine(n-26) Amlodepine(n-24) Cilnidipine(n-26)
Age yrs 58+-4 62+-5
BMI 26+-4 24+-2.6
Number with DM 12 14
Number with proteinuria 10 12
Day time SBP 164+-12 166+-14 152+-10 154+-11
Day time DSP 96+-8 100+-10 88+-8.4 91+-6.2
Day time PR 74+-9.8 72+-7.2 78+-7 64+-4
Night time SBP 140+-18 144+-16 132 +-12 136+-10
Night time DBP 92+-6.4 94+-8.4 88+-6 90+-8
Night time PR 60+-7 64+-8.4 66+-14 60+-8
Characteristics Pre Post PPI P Value
Brachial SBP 157 ± 18.6 122.8 ± 16.96 <0.0001
Central SBP 143 ± 14.37 111 ± 14.53 <0.0001
Central PP 63.9 ± 16 38.11 ± 11 <0.0001
AP 21.56 ± 7.22 10.22 ±5.73 <0.0001
Al 41.4 ± 9.16 24.05 ± 9.9 <0.0001
Pre PPI Pre Brachial VS Central SBP <0.05
Post PPI Post Brachial VS Central SBP <0.04
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